Vis børsmeldingen
(TET) platform at the Annual Meeting of the American Association for Cancer
Research (AACR), taking place on April 8-13, 2022 in New Orleans, Louisiana
(AACR22).
The presentation at AACR22 will be the first time Ultimovacs has shared data on
the TET platform with the R&D community. The data is part of the package that
helped inform the entry of TET into the current ongoing Phase 1 dose escalation
study in prostate cancer, TENDU. The 40 mcg and 400 mcg dose cohorts have now
been completed and is currently proceeding to the third and highest dose, 960
mcg.
The TET platform allows for the production of multiple therapeutic cancer
vaccines. It can be used to strengthen and increase T cell responses to cancer
cells by incorporating antigens that are specific to one type of cancer or
common to many tumor types into the platform. The vaccine used in the TENDU
trial contains prostate cancer-specific antigens. By combining cancer antigens
and the vaccine adjuvant in the same molecule, the TET platform can generate
vaccine candidates with a beneficial safety and administration profile,
presenting an opportunity to treat patients at an early stage of their disease.
The AACR poster presentation (#4160) is entitled “Promoting immunogencity of
synthetic long peptide vaccines based on in vivo IgG complex formation:
Preclinical evaluation and clinical entry of the TET platform”.
The poster will be presented on Wednesday Apr 13, 2022 in New Orleans Convention
Center, Exhibit Halls D-H, Poster Section 34.
The abstract is published in the online Proceedings of the AACR, and at the
Ultimovacs website under “Presentations and Publications”.
==ENDS==
About the TET-platform
The Tetanus-Epitope Targeting(TET)-platform offers an approach to strengthen and
increase T cell responses against cancer-specific peptides by combining cancer-
specific antigens and vaccine adjuvant in the same conjugated molecule, allowing
for a beneficial safety profile and simplifying administration. The platform
generates new, first-in-class cancer vaccine candidates that harness pre-
existing antibody responses resulting from standard tetanus vaccinations. TET
vaccine candidates can be tailored to many types of cancer.
About TENDU
The TENDU clinical trial (NCT04701021) is a first-in-human, Phase I study and
the first clinical trial of a vaccine from Ultimovacs’ Tetanus-Epitope Targeting
(TET)-platform. The trial is being conducted at the Oslo University Hospital,
Norway, and evaluates the safety of the vaccine in prostate cancer patients who
have relapsed after radical prostatectomy. The primary objective of the study is
to evaluate the safety and tolerability of three different doses of the vaccine.
Patients will receive the vaccine prior to obtaining standard-of-care treatment
consisting of radiation and antihormone therapy and will be followed for 6
months after the last dose of the vaccine to assess immunological responses such
as the activation of T cells and anti-tumor activity.
About Ultimovacs
Ultimovacs is developing immune-stimulatory vaccines to treat a broad range of
cancers. Ultimovacs’ lead universal cancer vaccine candidate UV1 targets human
telomerase (hTERT), present in 85-90% of cancers in all stages of tumor growth.
By directing the immune system to hTERT antigens, UV1 drives CD4 helper T cells
to the tumor to activate an immune system cascade and increase anti-tumor
responses. With a broad Phase II program, Ultimovacs aims to clinically
demonstrate UV1’s impact in multiple cancer types in combination with other
immunotherapies. Ultimovacs’ second technology approach, based on the
proprietary Tetanus-Epitope-Targeting (TET) platform, combines tumor-specific
peptides and adjuvant in the same molecule and entered Phase I studies in 2021.
For further information, please see www.ultimovacs.com or contact:
Carlos de Sousa, CEO
Email: carlos.desousa@ultimovacs.com (mailto:carlos.desousa@ultimovacs.com)
Phone: +47 908 92507
Anne Worsøe, Head of IR & Communication
Email: anne.worsoe@ultimovacs.com (mailto:anne.worsoe@ultimovacs.com)
Phone: +47 90686815
Mary-Ann Chang, LifeSci Advisors
Email: mchang@lifesciadvisors.com (mailto:mchang@lifesciadvisors.com)
Phone: +44 7483 284 853
This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to Section 5-12 in the Norwegian Securities Trading Act.
This stock exchange announcement was published by Joachim Midttun, Finance
Manager at Ultimovacs ASA, on March 9, 2022 at 16:30 CET.
Kilde
